Table of Contents

Foreword .................................................................................................................................................. ii
Acknowledgements .................................................................................................................................. iii
Abbreviations and Acronyms ................................................................................................................ iv
1.0 Introduction ......................................................................................................................................... 1
2.0 Definitions used in Leprosy ............................................................................................................... 2
3.0 Epidemiology ......................................................................................................................................... 3
  3.1 Characteristics of the Bacillus ......................................................................................................... 3
4.0 Transmission .......................................................................................................................................... 5
  4.1 Source of infection: ............................................................................................................................ 5
  4.2 Mode of transmission: ......................................................................................................................... 5
5.0 Diagnosis of Leprosy ........................................................................................................................... 6
  5.1 Early symptoms of Leprosy .............................................................................................................. 6
  5.2 Nerves commonly affected by Leprosy ............................................................................................. 8
  5.3 Classification of Leprosy .................................................................................................................... 9
    5.3.1 Importance of classification......................................................................................................... 9
    5.3.2 Classification ............................................................................................................................... 9
  5.4 WHO Disability Grading .................................................................................................................... 10
  5.5 Differential Diagnosis of Leprosy ................................................................................................... 10
    5.5.1 Macular lesions .......................................................................................................................... 10
6.0 Treatment .............................................................................................................................................. 11
  6.1 Aims of treatment ............................................................................................................................... 11
    Rifampicin: ........................................................................................................................................ 11
    Clofazimine/Lamprene: ...................................................................................................................... 11
    Dapsone: ........................................................................................................................................... 11
  6.2 Recommended Treatment Regimens ................................................................................................. 12
  6.3 Treatment for drug-resistant leprosy ................................................................................................ 12
  6.4 Reactions in Leprosy ......................................................................................................................... 12
    6.4.1 Types of Reactions: .................................................................................................................... 13
    6.4.2 Who can get leprosy Reactions? ............................................................................................... 13
    6.4.3 Precipitating factors: ................................................................................................................ 13
    6.4.4 Identification of people at risk: ................................................................................................. 13
    6.4.5 When do reactions occur? ........................................................................................................ 13
    6.4.6 Reversal Reaction .................................................................................................................... 14
    6.4.7 Erythema nodosum leprosum (ENL) ......................................................................................... 15
  6.5 Deformities and their Management .................................................................................................. 16
    6.5.1 Definitions ................................................................................................................................ 16
    6.5.2 Factors associated with deformity ............................................................................................ 16
    6.5.3 Prevention of Disabilities ......................................................................................................... 16
    6.5.4 Components of minimizing disabilities .................................................................................... 17
    6.5.5 Care of Eyes ................................................................................................................................ 17
7.0 Recording and Reporting .................................................................................................................... 18
  7.1 What should the programme contain? ............................................................................................. 18
8.0 Myths and Misconceptions of Leprosy ............................................................................................... 19
9.0 Prevention of Leprosy ............................................................................................................................ 20
  9.1 Prophylaxis ....................................................................................................................................... 20
  9.2 Vaccination ..................................................................................................................................... 20
10.0 Community Engagement in Leprosy ................................................................................................. 21
  10.1 Community screening .................................................................................................................... 21
  10.2 Role of the community in Prevention of Disabilities & Rehabilitation ........................................ 21
  10.3 Self-Care Groups (SCG) ............................................................................................................... 21
  10.4 Community Leprosy Prevention .................................................................................................... 21
11 Annexes ............................................................................................................................................... 23
Foreword

The Ministry of Health has made tremendous progress in reducing the burden of Leprosy in Zambia. Leprosy cases dropped from approximately 18,000 cases in 1980 to about 1000 cases in 1996. By the year 2000, the incidence rates had fallen to 0.67/10,000 population. Despite having achieved elimination target in the year 2000 (1 leprosy case per 10,000 population) Leprosy remains an important public health problem in Zambia and globally.

Every year we continue to record new cases of leprosy. In some provinces and districts leprosy cases are quite high pausing a threat of a resurgence. Particularly that over sixty percent of the leprosy cases that we are detecting are multibacillary, a form of leprosy that is infectious and easily transmissible from one person to the other.

These guidelines provide a step by step guidance in the detection, management and prevention of leprosy in our health facilities and the community. These guidelines are targeted for health facility managers, health care workers both in public and private facilities and the community. For us to maintain leprosy elimination levels, zero disability due to leprosy and avoid any resurgence of the disease in our country, all health care workers, including community health workers should be re-oriented on leprosy identification, care, treatment and prevention. Health training colleges and medical schools should include leprosy in their curricula. Community awareness about leprosy should be intensified so that we achieve our goal of eradicating leprosy in Zambia.

Leprosy is a notifiable disease, I therefore, urge all health care workers to ensure that leprosy cases are notified and reported to the national level promptly.

Lastly, I welcome these guidelines, developed with the support and active involvement of all stakeholders including civil society organizations. I urge all public and private health institutions, cooperating and implementing partners, and civil society organizations to plan the implementation of leprosy activities based on these guidelines.

DR KENNEDY MALAMA
PERMANENT SECRETARY-TS
Acknowledgements

The development of these guidelines was a result of the joint efforts of various organizations and institutions. The Ministry of Health extends its gratitude to the World Health Organization (Zambia) for their contribution towards the development of these guidelines.

The Ministry of Health further applauds the Directorate of Public Health for their stewardship and coordination roles, including the following members of the editorial team: Dr. Patrick Sailii Lungu (NTLP Manager, MOH), Dr. Lastone Chitembo (WHO TB/HIV NPO), Dr. Rhehab Chimzizi (Senior TB Technical Advisor, USAID), Dr. Monde Muyoyeta (CIDRZ), Ms Charity Habeenzu (ZATULET), Dr. Owen Ngalamika (UTH, MOH), Mr. Graham K Samungole (TB Officer, NTLP, MOH), Mr. Morton Khunga (Chief TB Officer, MOH), Mr. Tindo Liboma (TB Officer, NTLP, MOH), Ms. Clara Kasapo (TB Officer, NTLP, MOH), Mr. Charles Mang’ombe (TB/Leprosy Officer, MOH), Dr. Sulani Nyimbili (Epidemiologist, NTLP, MOH), Mr. Amos Nota (TB Technical Specialist, USAID Eradicate TB Project) and Ms. Judith Mzyece (TB Laboratory Focal Point, NTLP, MOH).

DR. ANDREW SILUMESII
DIRECTOR- PUBLIC HEALTH AND RESEARCH
### Abbreviations and Acronyms

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>BCG</td>
<td>Bacillus Calmette-Guerin</td>
</tr>
<tr>
<td>BI</td>
<td>Bacterial index</td>
</tr>
<tr>
<td>EHF</td>
<td>Eyes, Hands, Feet</td>
</tr>
<tr>
<td>ENL</td>
<td>Erythema nodosum leprosum</td>
</tr>
<tr>
<td>gm</td>
<td>gram</td>
</tr>
<tr>
<td>HIV/AIDS</td>
<td>Human Immunodeficiency Virus / Acquired Immunodeficiency Syndrome</td>
</tr>
<tr>
<td>ILEP</td>
<td>The International Federation of Anti-Leprosy Associations</td>
</tr>
<tr>
<td>MB</td>
<td>multibacillary</td>
</tr>
<tr>
<td>mg</td>
<td>milligram</td>
</tr>
<tr>
<td>MDT</td>
<td>multidrug therapy</td>
</tr>
<tr>
<td>PB</td>
<td>paucibacillary</td>
</tr>
<tr>
<td>PT</td>
<td>posterior tibial nerve</td>
</tr>
<tr>
<td>SDR</td>
<td>single-dose rifampicin</td>
</tr>
<tr>
<td>SSS</td>
<td>Slit-skin smear</td>
</tr>
<tr>
<td>SWP</td>
<td>Strong, Weak, Paralyzed</td>
</tr>
<tr>
<td>TID</td>
<td>three times a day</td>
</tr>
<tr>
<td>TB</td>
<td>tuberculosis</td>
</tr>
<tr>
<td>VMT</td>
<td>Voluntary Muscle Test</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organization</td>
</tr>
</tbody>
</table>
1.0 Introduction

Leprosy is an infectious disease caused by mycobacterium leprae (M. leprae), an acid-fast, rod-shaped bacillus. The disease mainly affects the skin, peripheral nerves, mucosa of the upper respiratory tract and the eyes. Leprosy is also known as Hansen's Disease, named after the scientist Dr. Gerhard Armaur Hansen from Norway, who discovered the bacillus in 1873.

In 2008 another species of mycobacterium, Mycobacterium lepromatous was discovered as a cause of a rare form of the disease known as Diffuse Lepromatous Leprosy (DLL). These guidelines, however, only address management of leprosy caused by Mycobacterium leprae.

Untreated Multibacillary (MB) leprosy is the main source of infection and may expel over 100,000,000 bacilli in nasal discharge daily. A susceptible host who inhales the air droplets containing these bacilli, may develop the disease. Leprosy is curable and treatment in the early stages can prevent disability.

Leprosy is most common in warm, wet areas in the tropics and subtropics. Leprosy is common in Asia, Africa, Central and South America. Ninety percent (90%) of the global leprosy cases are found in developing countries, including Zambia. The disease affects all age groups, sexes, racial groups and social levels. The average incubation period for leprosy is three to five years but can be up to 36 years. The reason for this lengthy incubation period is due to host immunity and slow multiplication of the bacillus.

National level statistics indicate that Zambia has reached the leprosy elimination target according to the World Health Organization (WHO) recommendation of less than one case per ten thousand population implying it is not a public health problem. However, there are still some areas in Zambia with high prevalence of leprosy compounded by poor data recording and surveillance.
2.0 Definitions used in Leprosy

- The **incidence** is the total number of new cases of leprosy that appear in a population during a given period.

- The **incidence rate** is the total number of new cases of leprosy that appear during a given period per 10,000 population.

- **Detection** is the identification, diagnosis and registration of all new cases in a population during a given time period.

- **Detection rate** is the identification, diagnosis and registration of all new cases in a population during a given period per 10,000 population.

- **Prevalence** is the number of all active cases on treatment in a population at a certain point in time.

- **Prevalence rate** is the number of all cases on treatment in a population at a certain point in time per 10,000 population.
3.0 Epidemiology

- Leprosy is most prevalent in tropical countries. Over the past 35 years, global prevalence had increased from 8.4 cases per 10,000 in 1966 to a peak of 12 per 10,000 population in 1985. There has been a steady decline with below 1 case per 10,000 in 2000.

- 107 out of 122 countries considered endemic in 1985 have reached elimination at the country level. At the end of 2000 leprosy was a public health problem only in 15 countries. Leprosy is largely concentrated in 6 countries accounting for 88% cases and these countries are India, Brazil, Nepal, Myanmar Madagascar and Mozambique.

- There were 208,619 new leprosy cases registered globally in 2018 according to World Health Organization official figures from 159 countries from the six WHO Regions. Based on the 184,212 cases at the end of 2018, prevalence rate corresponds to approximately 0.2/10,000.

- In 2019, Zambia registered a total of 208 new cases of leprosy. See table below

**Table 1: New cases of Leprosy by province in 2019**

<table>
<thead>
<tr>
<th>PROVINCE</th>
<th>Quarter 1</th>
<th>Quarter 2</th>
<th>Quarter 3</th>
<th>Quarter 4</th>
<th>Annual Total</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PB MB PB MB PB MB PB MB</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Western</td>
<td>2 10 2 25 2 7 1 8</td>
<td>5 50</td>
<td></td>
<td></td>
<td></td>
<td>55</td>
</tr>
<tr>
<td>Central</td>
<td>1 7 0 9 0 6 2 16</td>
<td>3 38</td>
<td></td>
<td></td>
<td></td>
<td>41</td>
</tr>
<tr>
<td>Northern</td>
<td>1 4 0 8 3 4 1 10</td>
<td>5 26</td>
<td></td>
<td></td>
<td></td>
<td>31</td>
</tr>
<tr>
<td>Copperbelt</td>
<td>0 1 1 7 5 6 0 1</td>
<td>6 15</td>
<td></td>
<td></td>
<td></td>
<td>21</td>
</tr>
<tr>
<td>Southern</td>
<td>2 2 2 2 0 5 0 1</td>
<td>4 10</td>
<td></td>
<td></td>
<td></td>
<td>14</td>
</tr>
<tr>
<td>Luapula</td>
<td>0 2 0 2 0 6 0 1</td>
<td>0 11</td>
<td></td>
<td></td>
<td></td>
<td>11</td>
</tr>
<tr>
<td>Lusaka</td>
<td>0 0 0 7 0 3 0 1</td>
<td>0 11</td>
<td></td>
<td></td>
<td></td>
<td>11</td>
</tr>
<tr>
<td>North Western</td>
<td>0 2 0 3 0 4 0 3</td>
<td>0 12</td>
<td></td>
<td></td>
<td></td>
<td>12</td>
</tr>
<tr>
<td>Eastern</td>
<td>0 1 0 3 0 0 0 2</td>
<td>0 6</td>
<td></td>
<td></td>
<td></td>
<td>6</td>
</tr>
<tr>
<td>Muchinga</td>
<td>0 0 0 2 0 3 0 1</td>
<td>0 6</td>
<td></td>
<td></td>
<td></td>
<td>6</td>
</tr>
<tr>
<td>TOTAL</td>
<td>6 29 3 68 10 44 4 44</td>
<td>23 185</td>
<td></td>
<td></td>
<td></td>
<td>208</td>
</tr>
</tbody>
</table>

3.1 Characteristics of the Bacillus

- Rod shaped, Acid fast Bacilli, (as it retains the red colour after stained with Ziehl Neelsen over a blue background)

*Figure 1: Acid fast bacilli Mycobacterium leprae*
• It is an intracellular organism that cannot be cultured and can only grow in the Nine-banded Armadillo (Dasypus novemcinctus) (see Figure 2 below)

![Nine-banded Armadillo](image.jpg)

**Figure 2: Nine-banded Armadillo**

• The bacillus has affinity for the peripheral nerves (Schwann cells)
• Remains suspended in the air for a long time
• Can be killed by sunlight
4.0 Transmission

4.1 Source of infection:
- The infected human being is considered the only source of infection.
- Infection capacity of multibacillary leprosy is 4-11 times higher than of Paucibacillary leprosy.
- On excretion from nasal secretions, M. Leprae will remain viable in air for longer periods.
- This prolonged survival makes airborne transmission a reasonable possibility.

4.2 Mode of transmission:
- For transmission to occur viable bacilli must leave the body of the patient and enter that of the contact.
- Prolonged exposure or close contact are considered necessary for transmission to occur.
- However, in susceptible individuals even short duration of contact may occasionally cause the disease.
- Therefore, it is likely that the respiratory tract and the skin are commonly the route of entry.
5.0 Diagnosis of Leprosy

The diagnosis of leprosy is based on the presence of at least one of the three cardinal signs:

1. Definite loss of sensation in a pale (hypo pigmented) or reddish skin patch;
2. Thickened or enlarged peripheral nerve with loss of sensation and/or weakness of the muscles supplied by that nerve; or
3. Presence of acid-fast bacilli in a slit-skin smear. (confirmatory test)

5.1 Early symptoms of Leprosy
- Hypo pigmented skin patches

Figure 3: Hypopigmented skin patches due to M. leprae

Figure 4: Skin lesions on the thigh of a person with leprosy
- Numbness in the hands and feet
- Facial palsy
- Weakness in the hands and the feet
- Thickening of the skin especially on the face
- Nodules and plaques

Figure 5: Nodules and plaques due to M. leprae

Figure 6: Sharply demarcated reddish brown plaques and nodules

Figure 7: Nodules and thickening of facial skin due to M. leprae (01)
5.2 Nerves commonly affected by Leprosy

- Supraorbital nerve - face.
- Greater auricular - neck.
- Upper radial - lateral upper arm.
- Upper ulna - near elbow medially.
- Superficial radial - near wrist.
- Lateral popliteal - Head of fibula.
- Posterior tibia below internal malleolus.

Figure 8: Nodules and skin thickening due to M. leprae (02)

Figure 9: Main nerves commonly affected by M. leprae
5.3 Classification of Leprosy

The classification of leprosy patients is not due to the difference in the strains of the causative organisms. It can be classified based on number of skin lesions or number of bacilli on skin smears. The range of clinical manifestations depends on the infected individual’s immune response to leprosy bacilli. There is only one strain of the mycobacterium leprae.

5.3.1 Importance of classification

- To determine the duration of treatment.
- To determine the prognosis in the disease course and possible complications.
- For research purposes.

5.3.2 Classification

- WHO recommends Leprosy patients to be classified as either Multibacillary (MB) or Paucibacillary (PB).

If there is doubt about the classification, the patient should be classified as MB and be treated accordingly.
5.3.2.1 **Paucibacillary (tuberculoid)**
- 5 lesions.
- Lesions are asymmetrically distributed
- Definite loss of sensation on the lesions.
- Only ONE nerve trunk is enlarged.
- Negative Slit Skin Smear (SSS).

5.3.2.2 **Multibacillary (lepromatous)**
- More than 5 lesions.
- Lesions are symmetrically distributed.
- Some degree of loss of sensation on the lesions.
- Many nerve trunks are enlarged.
- Positive Slit Skin Smear.

5.4 **WHO Disability Grading**

5.3.3.1 **Hands and feet**
- Grade 0: No anaesthesia, no visible deformity or damage
- Grade 1: Anaesthesia present, but no visible deformity or damage
- Grade 2: Visible deformity or damage present

5.3.3.2 **Eyes**
- Grade 0: No eye problem due to leprosy; no evidence of visual loss
- Grade 1: Eye problem due to leprosy present, but vision not severely affected as a result (vision 6/60 or better; can count fingers at six metres)
- Grade 2: Severe visual impairment (vision worse than 6/60; inability to count fingers at six metres)

5.5 **Differential Diagnosis of Leprosy**
Below is a list of differential diagnoses for Leprosy. However, the list is not exhaustive:

5.5.1 **Macular lesions**
- Birth mark
- Vitiligo
- Pityriasis alba
- Pityriasis rotunda
- Tinea versicolor
- Erythema dyschromicum (Ashy dermatosis)
- Localised scleroderma (Morphea)
- Lchtyosis vulgaris
- Post-inflammatory hypopigmentation
- Tinea corporis
- Granuloma multiforme
- Psoriasis
- Lupus vulgaris
- Discoid lupus erythematos 5.5.2 **Nodular skin lesions**
- Disseminated anergic cutaneous leishmaniasis
- Post kala-azar-dermal leishmaniasis
- Kaposi’s sarcoma
- Neurofibromatosis
6.0 Treatment

6.1 Aims of treatment

- To cure the patient (using multi drug therapy)
- To render patient non-infectious and thus control the spread of leprosy
- To prevent the development of multi drug resistant leprosy

Drugs used in leprosy as recommended by WHO are a combination of rifampicin, clofazimine and dapsone (MDT). The duration of treatment for PB leprosy is 6 months and 12 months for MB leprosy.

Rifampicin:

- Bactericidal drug
- A single 600-mg monthly dose is almost as effective as daily rifampicin for treatment purposes
- Given once a month
- The slow multiplication rate of M. leprae (about once in 12 days) justifies the use of rifampicin as monthly therapy
- In this dosage it is almost nontoxic
- Patient must be warned that it will make the urine red for few hours after its intake

Clofazimine/Lamprene:

- Bactericidal and Bacteriostatic
- This is most active when administered daily,
- Is well tolerated and virtually nontoxic in the dosage used for MDT.
- The drug causes brownish-black discoloration and dryness of the skin but although this disappears within a few months after stopping treatment and this should be explained to patients starting the MDT regimen for MB leprosy.
- It also has anti-inflammatory activity and is used to treat type 2 Lepra reaction

Dapsone:

- Bacteriostatic; this is very safe in the dosage used in MDT, usually at a dose of 1-2 mg per kg/day
- Side effects are rare but the main one is allergic reaction, causing itchy skin rashes and exfoliative dermatitis. Therefore, patients known to be allergic to any of the sulpha drugs should not be given dapsone
- In a few cases, there is a feeling of 'heat' or difficulty in sleeping
- A mild haemolytic anaemia is common
6.2 Recommended Treatment Regimens

Table 2: Recommended leprosy treatment regimens

<table>
<thead>
<tr>
<th>Age group</th>
<th>Drug</th>
<th>Dosage and frequency</th>
<th>Duration (months)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>MB</td>
</tr>
<tr>
<td>Adult</td>
<td>Rifampicin</td>
<td>600 mg once a month</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Clofazimine</td>
<td>300 mg once a month and 50 mg daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dapsone</td>
<td>100 mg daily</td>
<td></td>
</tr>
<tr>
<td>Children (10-14 years)</td>
<td>Rifampicin</td>
<td>450 mg once a month</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Clofazimine</td>
<td>150 mg once a month and 50 mg daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dapsone</td>
<td>50 mg daily</td>
<td></td>
</tr>
<tr>
<td>Children &lt;10 years old or &lt;40 kg</td>
<td>Rifampicin</td>
<td>10 mg/kg once month</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Clofazimine</td>
<td>100 mg once a month, 50 mg twice weekly</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dapsone</td>
<td>2 mg/kg daily</td>
<td></td>
</tr>
</tbody>
</table>

Guidelines for the diagnosis, treatment and prevention of leprosy © World Health Organization 2018

6.3 Treatment for drug-resistant leprosy

The World Health Organization Guidelines Development Group recommends for leprosy patients with rifampicin resistance to be treated using at least two of the following second-line drugs: clarithromycin, minocycline, or a quinolone (ofloxacin, levofloxacin or moxifloxacin), plus clofazimine daily for 6 months, followed by clofazimine plus one of the second-line drugs daily for an additional 18 months.

In case of rifampicin plus ofloxacin resistance, a quinolone should not be chosen; therefore, the recommended regimen is clarithromycin, minocycline and clofazimine for 6 months followed by clarithromycin or minocycline plus clofazimine for an additional 18 months.*

Table 3: Recommended Drug Resistant Leprosy regimens

<table>
<thead>
<tr>
<th>Resistance type</th>
<th>Treatment</th>
<th>First 6 months (daily)</th>
<th>Next 18 months (daily)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rifampicin resistance</td>
<td>Ofloxacin 400 mg* + minocycline 100 mg + clofazimine 50 mg</td>
<td></td>
<td>Ofloxacin 400 mg* OR minocycline 100 mg + clofazimine 50 mg</td>
</tr>
<tr>
<td></td>
<td>Ofloxacin 400 mg* + clarithromycin 500 mg + clofazimine 50 mg</td>
<td></td>
<td>Ofloxacin 400 mg* + clofazimine 50 mg</td>
</tr>
<tr>
<td>Rifampicin and ofloxacin resistance</td>
<td>Clarithromycin 500 mg + minocycline 100 mg + clofazimine 50 mg</td>
<td>Clarithromycin 500 mg OR minocycline 100 mg + clofazimine 50 mg</td>
<td></td>
</tr>
</tbody>
</table>

*Guidelines for the diagnosis, treatment and prevention of leprosy © World Health Organization 2018

*Ofloxacin 400 mg can be replaced by levofloxacin 500 mg OR moxifloxacin 400 mg
6.4 Reactions in Leprosy
The term reaction is used to describe the appearance of signs and symptoms of acute inflammation in the lesions of a patient with leprosy. It has to be pointed out that reactions is not something peculiar to leprosy, but that it is an immunological response of the body with the following signs of inflammation:
- Redness.
- Raised temperature.
- Pain.
- Swelling and loss of function.

6.4.1 Types of Reactions;
There are two types of reactions:
- Reversal reaction - Type 1.
- Erythema Nodosum Leprosum (ENL) – Type 2. ENL is more common in MB Leprosy

NB: It is much more urgent to recognize and treat the lepra reaction so as to prevent nerve damage than to decide which type the reaction is; the treatment of nerve damage is much the same whichever type of reaction is present.

6.4.2 Who can get leprosy Reactions?
- Almost any person with leprosy is at risk of getting a reaction with only one two patches and no nerve involvement.
- 25-30% leprosy patients experience reactions or nerve damage at one time or another.

6.4.3 Precipitating factors:
- Inter-current infections (viral, malaria).
- Anaemia.
- Mental and physical stress.
- Puberty.
- Pregnancy.
- Parturition.
- Surgical interventions.

6.4.4 Identification of people at risk:
- Patient within 6-8 months of starting MDT.
- Pregnant and lactating mothers.
- Adolescents (10-25 years of age).
- Patients with other infections like TB.
- Patients with lesions near or around the eye.

6.4.5 When do reactions occur?
- Before treatment.
- At diagnosis.
- During treatment.
- After treatment has been completed.
### 6.4.6 Reversal Reaction

#### 6.4.6.1 Recognition of reversal reaction

<table>
<thead>
<tr>
<th>Site</th>
<th>Mild</th>
<th>Severe</th>
</tr>
</thead>
</table>
| **Skin**              | • Swelling and redness  
• burning in patches                                                      | • Swelling, redness and pain in patches with fever and generalised body malaise and possible ulceration |
|                       |                                                                      | • Pain and tenderness  
• Loss of function.  
• Duration longer than 6 weeks                                           |
| **Nerves**            | • No pain, sometimes tingling or burning,  
• No loss of function.  
• Duration less than 6 weeks                                              | • Swelling, redness, pain, ulceration of the patches and/or oedema of hands and feet  
• Pain, tenderness and loss function of the nerve trunks  
• Duration more than 6 weeks                                               |
| **Skin and nerves together** | • Swelling in patches,  
• Some nerves tenderness  
• No loss of function.  
• Duration less than 6 weeks                                              |                                                                       |

**Fig. 136** Reversal reaction in a patient with borderline (BT) leprosy  
**Fig. 137** The same patient (Fig. 136) after treatment with prednisolone
6.4.6.2 Treatment for mild reactions in the field
1. Continue anti-leprosy treatment, do not lower the dosage
2. Give an analgesic (Aspirin, Butazolidine etc.)
3. If there is nerve tenderness, rest the affected limb (sling or splint the arm)
4. See the patient again after 1-2 weeks and tell him to return at once should the reaction become more severe

6.4.6.3 Treatment of severe Reaction
1. Continue anti-leprosy treatment
2. Start treatment with steroids (prednisolone) - no other drugs are effective
   - 40mg daily for 2 weeks
   - 30mg daily for 2 weeks
   - 20mg daily for 2 weeks
   - 15mg daily for 2 weeks
   - 10mg daily for 2 weeks
   - 5mg daily for 2 weeks
3. Severe reaction is an emergency. The patient should be transferred to the specialised centres as soon as possible.
4. If a ‘flare-up occurs the dosage may be raised again by one step for a further two weeks.

6.4.7 Erythema nodosum leprosum (ENL)
This reaction occurs in patients with MB Leprosy, and usually starts 6 months or more after the start of anti-leprosy treatment. However, reactions may occur earlier after the start of Anti Leprosy treatment.

6.4.7.1 Cause of the reaction:
The reaction is caused by an allergic response of the body to leprosy bacilli, particularly when they have been killed and are breaking up. It is not directly due to MDT. This reaction occurs most commonly in areas of the body where leprosy bacilli are present such as the skin, nerves, eyes, testicles and lymph nodes. It can also, however, occur in the joints and kidneys. The signs of this reaction are local inflammation; that is pain, swelling and redness; and general malaise and fever.

6.4.7.2 Recognition of ENL

<table>
<thead>
<tr>
<th>Site</th>
<th>Mild</th>
<th>Severe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Skin</td>
<td>Few crops of red, tender nodules</td>
<td>Many crops of red, tender nodules</td>
</tr>
<tr>
<td></td>
<td>Few nodules present at one time</td>
<td>Many nodules present at one time</td>
</tr>
<tr>
<td></td>
<td>Mild fever and malaise</td>
<td>Severe fever and malaise</td>
</tr>
<tr>
<td></td>
<td>A few nodules may ulcerate</td>
<td>Many nodules may ulcerate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Patient very ill</td>
</tr>
<tr>
<td>Nerves</td>
<td>No pain</td>
<td>Pain and/or tenderness</td>
</tr>
<tr>
<td></td>
<td>Tenderness and/or swelling</td>
<td>Swelling and/or loss of function</td>
</tr>
<tr>
<td></td>
<td>No loss of function</td>
<td></td>
</tr>
<tr>
<td>Eyes</td>
<td>There are no “Mild” eyes reactions</td>
<td>Pain</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Reduction in vision</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Redness around limbus</td>
</tr>
<tr>
<td>Testicles</td>
<td>No pain, tenderness</td>
<td>Pain, tenderness and swelling</td>
</tr>
<tr>
<td></td>
<td>No swelling</td>
<td></td>
</tr>
</tbody>
</table>
6.4.7.3 General principles for treatment of ENL
   a) Control acute pain
   b) Halt eye damage
   c) Bed rest
   d) Treatment of specific symptoms appropriately

6.4.7.4 Mild ENL:-
   a) Continue anti-leprosy treatment in full dose. If there is tenderness of nerves rest of the affected limb.
   b) Analgesia (Aspirin, Panadol) when necessary
   c) Chloroquin 250mg TID for 1-2 weeks
   d) Stibophen

6.4.7.5 Severe ENL:-
   a) Continue anti-leprosy treatment in full dose.
   b) Refer the patient to the hospital if the reaction involves nerves or eyes.
   c) Corticosteroids as indicated in type one reaction.
   d) Lamprene in addition to MDT.
   e) Thalidomide: start 200-400mg/day and reduce to 50-100mg/day after one or two weeks.

6.5 Deformities and their Management
6.5.1 Definitions
   Deformity is defined as any deviation from normal appearance of any part/s of the body. It may or may not be accompanied by disability.

   Disability means the inability of a person to do normal work.
   Disability and deformity primarily result directly or indirectly from function loss of peripheral nerves supplying eyes, hands and/or feet.

6.5.2 Factors associated with deformity

<table>
<thead>
<tr>
<th>Type of Disease</th>
<th>Deformities/disabilities are commonly found in patients with MB leprosy.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration of disease</td>
<td>The longer the disease lasts, the more prone to developing deformities.</td>
</tr>
<tr>
<td>Nerve thickening</td>
<td>Nerve thickening has often been associated with deformities due to functional loss of the organ being supplied by that nerve.</td>
</tr>
<tr>
<td>Age</td>
<td>Deformities due to Leprosy are more frequent in the 20 to 50-year age-group. However, they may develop in any age-group.</td>
</tr>
<tr>
<td>Sex</td>
<td>Deformities are less common in women than in men.</td>
</tr>
<tr>
<td>Occupation</td>
<td>Deformities and disabilities are more commonly found among manual workers, since they are more frequently exposed to injuries and infections.</td>
</tr>
</tbody>
</table>
6.5.3 **Prevention of Disabilities**
The most effective way to prevent disabilities is to prevent primary nerve damage. This implies:
- Early diagnosis
- Early identification of reactions
- Drug treatment
- Early referral of Patients with reactions to the next level for further management.

6.5.4 **Components of minimizing disabilities**
- Emphasis on good communication- listening to patients, listening to colleagues and encouragement of patients by staff and staff by their seniors.
- Emphasis on patients role in self-help:
  - Convince the patient that care is useful
  - Encourage patient to avoid skin cracks and wounds
  - Help patients to understand that minimising of disabilities is totally their responsibility, but the health worker is willing to render support

6.5.5 **Care of Eyes**
- Patient should avoid eye dryness e.g.
  - Check daily for signs of irritation.
  - Wash the face
  - Think blink
  - Exercise

Prevention of disabilities is teamwork of health workers and the patients. The patient MUST be taught to UNDERSTAND that he plays a major role in preventing disabilities by:

- Thinking before doing an activity
- Taking extra care of the hands and feet
- Inspecting daily on hands and feet for warm spots
- Soaking, oiling and exercising- Voluntary Muscle Testing and Sensory Testing.
- Correct footwear.
7.0 Recording and Reporting

Recording and Reporting is very important in the Leprosy programme for the capturing of operational Data. Accurate Recording and Reporting is important at all health service delivery points and data captured should be transmitted to higher level. Data captured should be used for planning purposes at all levels.

7.1 What should the programme contain?
The purposes of a leprosy control programme are reduction in the incidence of leprosy in the programme area by:
- a. Case finding
- b. Case holding
- c. Case management leading to arrest or cure of the disease.

7.1.1 Case finding:
- a) Number of patients on register at the beginning of the period under review according to age groups, classification and disability proportion.
- b) Number of newly registered patients:
  - New cases
  - Previously treated
  - Transferred in- according to age groups, classification and disability proportion.

7.1.2 Case holding:
- a) Patients transferred out, died and lost from control according age groups, classification and disability proportion.
- b) Attendance rate for Lepromatous and Tuberculoid cases.

7.1.3 Case management
- a) Patients cured (disease arrested) and discharged.
- b) Patients developing complication; reactions
- c) Non improvement or worsening of condition (suspected drug resistance)
- d) Relapses (reactivation after discharge)
- e) Hospital admission
- f) Disability prevention and care; health Education, follow-up, exercises, shoe making programme.

### Reasons for Not Attending Appointments and Actions to be Taken

<table>
<thead>
<tr>
<th>Reasons for missing appointments</th>
<th>Actions to be taken</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Patient has moved out of your area</td>
<td>• Record this information in the treatment register</td>
</tr>
<tr>
<td>• Patient is taking treatment at another health centre</td>
<td>• Record this information in the treatment register</td>
</tr>
<tr>
<td>• No confidence in the treatment services</td>
<td>• Improve the quality of services to regain the community and patients' confidence.</td>
</tr>
<tr>
<td>• Patient had unpleasant side effects which is attributed to the treatment</td>
<td>• It is important to reassure the patient if it's a minor side effect and refer if it's a major side effect for further investigations and management.</td>
</tr>
<tr>
<td>• Non-availability of services</td>
<td>• Make efforts to establish services and inform the community.</td>
</tr>
</tbody>
</table>
| • Patient thinks that his/her condition has cleared completely | • Assess the patient and review the records to confirm whether the patient is cured or not.  
• Assessment of the patient should be done clinically or Slit Skin Smear where possible. |
8.0 Myths and Misconceptions of Leprosy

- A curse from God.
- Patients considered to be unclean.
- Patients believed to be practicing witchcraft.
- People believe that Leprosy is incurable.
- People believe that Leprosy can be transmitted by handshake.
- People believe that having sex worsens the disease.
9.0 Prevention of Leprosy

9.1 Prophylaxis
Leprosy is associated with important clinical and social consequences. Zambia as a country has adopted the recommendation to give prophylaxis to contacts of new leprosy patients to curb the further spread of the disease.

The guidelines recommend the use of single-dose rifampicin (SDR) as preventive treatment for adult and child (2 years of age and above) contacts of leprosy patients, after excluding leprosy and tuberculosis (TB) disease and in the absence of other contraindications. Before giving prophylaxis to the contacts, ensure that you try and get consent of the index case to disclose his/her disease to the contacts.

Because Zambia is a high burden country for Mycobacterium Tuberculosis, caution must be exercised. MTB disease must be ruled out before administration of SDR.

Rifampicin is the drug of choice. Recommended dosage schedules for Single Dose Rifampicin (SDR) are given in Table below.

<table>
<thead>
<tr>
<th>Age/weight</th>
<th>Rifampicin single dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>15 years and above</td>
<td>600 mg</td>
</tr>
<tr>
<td>10 – 14 years</td>
<td>450 mg</td>
</tr>
<tr>
<td>Children 6 – 9 years (weight ≥20 kg)</td>
<td>300 mg</td>
</tr>
<tr>
<td>Children &lt;20 kg (≥2 years)</td>
<td>10 – 15 mg/kg</td>
</tr>
</tbody>
</table>

9.2 Vaccination
BCG at birth is effective at reducing the risk of leprosy; therefore, its use as a preventative measure should be maintained.
10.0 Community Engagement in Leprosy

10.1 Community screening
Trained Community Health Workers (CHWs) are able to identify presumptive leprosy cases in the community and are very important in leprosy control. After identifying a case their next role is to refer. At community level the CHWs are able to detect a presumptive leprosy case when a person has one or more of the following signs and symptoms:

- Presence of pale (lighter than normal skin) or copper coloured skin patches or red patches. These patches are dry, non-itchy or there may be loss of hairs
- Numbness or impairment or loss of sensation on the hands and or feet – with thickening of peripheral nerves
- Weakness and difficulty in normal movement of fingers/thumb/wrist/ toes/ankles or eyelids
- Painless injuries, blisters, burns or ulcers in hands and feet
- Deformities such as clawing of fingers/thumb, clawing of toes, high stepping gait due to foot-drop or inability to close eyes properly.

10.2 Role of the community in Prevention of Disabilities & Rehabilitation
There are many ways in which the complications of leprosy can be minimized by practicing good self-care at home. People need to be informed clearly about the actions they can take at home that are appropriate for their particular situation. The health worker may be the main source of advice, but others may be recruited to help:

- Family members can help and encourage the person to do what is needed on a regular basis.
- Other people affected by leprosy can show how they have been able to look after themselves at home. Self-care groups have been able to look after themselves at home. Self-care groups have been started in some communities. A number of people with self-care needs meet together regularly to discuss the practicalities of self-care. These groups are often surprisingly supportive and can be very motivating for members.

10.3 Self-Care Groups (SCG)
A short description of Self-Care Groups is given here. In annex 2 a description is given on principles and advantages of a self-care group.

Definition
A self-care group is a group of people affected by leprosy trying to solve their problems due to leprosy.

Objective
The general objective is to prevent or reduce disabilities in their members.

Specific objective
- To enable members to support each other in finding solutions for their own (physical, psychological, or economic) problems related to leprosy
- To encourage group members in using locally available materials for their treatment
- To monitor the participant efficiently and effectively
- To refer promptly for special care (for instance reconstructive surgery, rehabilitation)
- To increase the self-esteem and self-confidence of the members in order to be able to participate more actively in society
- To decrease fear for leprosy among the participants, their family and involved staff

10.4 Community Leprosy Prevention
Without identifying all infectious cases in the community Leprosy will continue to spread among the population. The following can help to reduce the spread of leprosy:
• Demand creation for community to seek early diagnosis and treatment
• Community Health education to raise suspicion of leprosy by the community members
• Community Capacity building on basic facts about leprosy, signs and symptoms, and mode of transmission will improve early diagnosis and treatment.
• Community knowledge that leprosy disease is curable will reduce stigma and discrimination
• Community sensitization on the importance of single dose rifampicin chemoprophylaxis
### Annex 1: Documents Used in Leprosy Recording and Reporting.

#### QUARTERLY LEPROSY STATISTICAL REPORT AND DRUG ORDER FORM.

<table>
<thead>
<tr>
<th>Name of Clinic:</th>
<th>District:</th>
<th>District Population:</th>
<th>Quarter/Year</th>
<th>Name of Reporting Officer:</th>
<th>Designation</th>
<th>Date:</th>
</tr>
</thead>
</table>

1. Registered by the end of the Previous Quarter.

<table>
<thead>
<tr>
<th>ADULT</th>
<th>CHILDREN</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>MB</td>
<td>PB</td>
<td>MB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PB</td>
</tr>
</tbody>
</table>

Total (1)

2. New Cases detected during this Quarter

<table>
<thead>
<tr>
<th>ADULT</th>
<th>CHILDREN</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>MB</td>
<td>PB</td>
<td>MB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PB</td>
</tr>
</tbody>
</table>

Total (2)

#### New Child cases - Age breakup

- New cases ≤ 5 years of age
- New cases between 6-15 years of age

#### New cases by gender

<table>
<thead>
<tr>
<th>Male</th>
<th>Female</th>
<th>Total</th>
<th>% Female</th>
</tr>
</thead>
</table>

#### New cases with grade 2 disabilities

- Adult
- Children
- Total

#### % of grade 2 disabilities

- Foreign born cases
- New foreign born cases

#### Retreatment cases

<table>
<thead>
<tr>
<th>ADULT</th>
<th>CHILDREN</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>MB</td>
<td>PB</td>
<td>MB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PB</td>
</tr>
</tbody>
</table>

#### Number of relapses detected

- All other retreatment cases

3. Removed from Register during the Quarter of Report.

<table>
<thead>
<tr>
<th>ADULT</th>
<th>CHILDREN</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>MB</td>
<td>PB</td>
<td>MB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PB</td>
</tr>
</tbody>
</table>

Total (3)

4. Cases registered for treatment at the end of Quarter (including new and retreatment cases)

<table>
<thead>
<tr>
<th>ADULT</th>
<th>CHILDREN</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>MB</td>
<td>PB</td>
<td>MB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PB</td>
</tr>
</tbody>
</table>

#### Type I and Type II Reactions in leprosy

<table>
<thead>
<tr>
<th>ADULT</th>
<th>CHILDREN</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>MB</td>
<td>PB</td>
<td>MB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PB</td>
</tr>
</tbody>
</table>

#### Treatment outcome for patients

- New MB cases who started treatment
- Of them, how many completed treatment within 18 months?
- Of them, how many were ‘lost to follow-up’?
- New PB cases who started treatment
- Of them, how many completed treatment within 9 months?
- Of them, how many were ‘lost to follow-up’?

#### ANTI-LEPROSY DRUG STOCK DURING THE PERIOD AND ORDER FOR NEXT QUARTER (In Blisters)

<table>
<thead>
<tr>
<th>BLISTERS</th>
<th>In Stock</th>
<th>Received</th>
<th>Issued</th>
<th>Balance</th>
<th>Required</th>
</tr>
</thead>
<tbody>
<tr>
<td>MB (adult)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PB (adult)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MB (child)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PB (child)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Serial No.</td>
<td>District No.</td>
<td>Name in Full</td>
<td>Sex M/F</td>
<td>Age</td>
<td>Address</td>
</tr>
<tr>
<td>-----------</td>
<td>--------------</td>
<td>--------------</td>
<td>---------</td>
<td>-----</td>
<td>---------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year</td>
<td>JAN</td>
<td>FEB</td>
<td>MAR</td>
<td>APR</td>
<td>MAY</td>
</tr>
<tr>
<td>------</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Annex 2: Principle of Self Care Groups (SCG)

The main principle of the SCG is that members participate in all aspects of the group. They should be encouraged to decide about organizational matters within the group or topics to be discussed. Ideally the facilitator of the group only guides the activities during a meeting.

In a SCG, it is the members who prevent and reduce disabilities, not the facilitator. The members are supposed to practice self-care daily at home by using local materials. They should use the group meetings to control their improvements and to exchange experiences.

Advantages of Self Care Groups
Coming together in a group to approach similar problems brings many advantages:

- The understanding of the members about self-care will increase, because special time is reserved for explanations, discussions and practice
- Better understanding will then contribute to independent and confident management of disabilities by each member at home
- The peer pressure in the group helps them to be serious about practicing self-care at home
- Difficulties can be solved directly; problems can be discussed together, and experiences exchanged.
- Sharing problems may lessen the burden of individual members
- In a relaxed atmosphere of the group, asking and talking will be easier than it might be during limited consultation time with the health worker in the health center. For example, further ideas concerning socio-economic issues can be developed
- Helping and supporting each other gives people a good feeling about themselves and increases self-confidence
- The burden of wound healing is reduced in terms of work, funds and time
Annex 3: Leprosy Appointment Card

Type of Leprosy: MB………………… PB…………………
Date of Diagnosis: ………………………………………
Date of Treatment Started:
…………………………………………

Type of Patient
New ☐ Transfered in ☐
Relapse ☐ Treatment resumed ☐

<table>
<thead>
<tr>
<th>JAN</th>
<th>FEB</th>
<th>MAR</th>
<th>APR</th>
<th>MAY</th>
<th>JUN</th>
<th>JUL</th>
<th>AUG</th>
<th>SEP</th>
<th>OCT</th>
<th>NOV</th>
<th>DEC</th>
<th>Total MDT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Next appointment date for drug collection
Enter date

Date of Treatment completed:
…………………………………………
Annex 4: Follow-up Examinations

### Follow-up Examinations

**VMT**

<table>
<thead>
<tr>
<th></th>
<th>RIGHT SIDE</th>
<th>LEFT SIDE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>DATE</strong></td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Eyelid Strength</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Blink Normal</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>5th Finger In</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Thumb up (palm upwards)</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Wrist up</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Foot up</td>
<td>Yes</td>
<td>Yes</td>
</tr>
</tbody>
</table>

**ST**

<table>
<thead>
<tr>
<th>DATE</th>
<th>PALMS Right</th>
<th>Left</th>
<th>SOLES Right</th>
<th>Left</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes/No</td>
<td></td>
<td>Yes/No</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yes/No</td>
<td></td>
<td>Yes/No</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yes/No</td>
<td></td>
<td>Yes/No</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yes/No</td>
<td></td>
<td>Yes/No</td>
<td></td>
</tr>
</tbody>
</table>

*Key: S = Strong, W = Weak, P = Paralysed*
Collected dosages of MDT  Enter the date in the box below the month of collection

<table>
<thead>
<tr>
<th>Year</th>
<th>JAN</th>
<th>FEB</th>
<th>MAR</th>
<th>APR</th>
<th>MAY</th>
<th>JUN</th>
<th>JUL</th>
<th>AUG</th>
<th>SEP</th>
<th>OCT</th>
<th>NOV</th>
<th>DEC</th>
<th>Extra</th>
<th>Total MDT</th>
</tr>
</thead>
</table>

RFT Assessment

Date _________________________

<table>
<thead>
<tr>
<th>R</th>
<th>VMT</th>
<th>L</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>eyelid strength or gag reflex</td>
<td></td>
</tr>
<tr>
<td></td>
<td>knee reflex</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5th finger in</td>
<td></td>
</tr>
<tr>
<td></td>
<td>thumb up</td>
<td></td>
</tr>
<tr>
<td></td>
<td>wrist up</td>
<td></td>
</tr>
<tr>
<td></td>
<td>foot up</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>R</th>
<th>DISABILITY</th>
<th>L</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>eye</td>
<td></td>
</tr>
<tr>
<td></td>
<td>hand</td>
<td></td>
</tr>
<tr>
<td></td>
<td>foot</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>R</th>
<th>VISUAL ACTIVITY</th>
<th>L</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>EYE SENSATION</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Nerves</th>
<th>median</th>
<th>ulnar</th>
<th>peroneal</th>
<th>tibial</th>
</tr>
</thead>
<tbody>
<tr>
<td>R</td>
<td>L</td>
<td>L</td>
<td>R</td>
<td>L</td>
</tr>
<tr>
<td>L</td>
<td>R</td>
<td>R</td>
<td>L</td>
<td>L</td>
</tr>
<tr>
<td>tender</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Summary on RFT

skin _________________________
nerves _________________________
eyes _________________________
hands _________________________
feet _________________________

Name examiner:
Function:
Signature:
Annex 5: Testing and Recording Sensation, Strength of Hands and Feet

**Hand and foot mapping, including sensation test (ST)**

1. Mark any wounds, open cracks, clawing of digits and bone loss on the Leprosy Control Patient Record Card (PRC).

2. Support the patient’s hand/foot so that fingers/toes are well supported to prevent joint movement during the test.

3. Explain the test to the patient. Rehearse it with her. Then test. A book should be held between the patient’s eyes and hand so that she cannot see. Dent the patient’s skin in 1-2mm at dot sites using a ballpoint pen - asking the patient to point to the exact site whenever she feels. The stimuli should be irregular in timing and placing.

Compare sensation of the little finger with that over the thumb and sensation of one hand with the other, to see if there is a difference. Compare findings with those shown on any earlier records.

Look for any CHANGE. Make sure that the change is real and not due to inaccuracies in testing.

Record: ✓ if the patient feels, × if he does not.
Voluntary Muscle Test (VMT) Hand and Foot record

Tests should be in two clear parts

1. A check of range of movement to see whether normal, reduced or absent due to muscle paralysis. Black arrows → show movement required.

2. If movement is normal, a test for resistance. Press gently whilst asking the patient to maintain the position; resisting the pressure as strongly as possible. Then press gradually more firmly and judge whether resistance is normal, reduced or absent. White arrows ← show where resistance is applied.

3. Always compare the right hand or foot with the left.

<table>
<thead>
<tr>
<th>1 Is movement full?</th>
<th>2 Is resistance full?</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Little Finger In</strong>... a test of ulnar nerve function</td>
<td>Patient tries to hold a card between ring and little fingers. Assessor pulls card very gently.</td>
</tr>
<tr>
<td>Hold these 3 fingers straight</td>
<td></td>
</tr>
<tr>
<td><strong>Straight Thumb up</strong>... a test of median nerve function</td>
<td>Assessor resists at side of thumb (not at front or back)</td>
</tr>
<tr>
<td>Patient moves thumb base fully out and across</td>
<td></td>
</tr>
<tr>
<td><strong>Wrist up</strong>... a test of radial nerve function</td>
<td></td>
</tr>
<tr>
<td><strong>Foot up</strong>... a test of peroneal nerve function</td>
<td></td>
</tr>
</tbody>
</table>
Annex 6: Testing and Recording of the Eyes

**Blink Record**

Observe the patient’s blink as you talk with him while he is not thinking about his eyes. If he knows you are examining his eyes he may stop blinking. Watch for these problems:

1. Lashes turned in and touching the eye
2. Patient never or rarely blinking in one or both eyes
3. Incomplete closure during blink (observe from the side and see if upper and lower lashes meet).
4. Redness and injury affecting the lower part of the eye not covered during blink.
5. Lower lid hanging away from the eye. Overflowing tears.

Record **Yes** or **No** beside **Blink Normal**. If answering **No**, list any problems seen and any patient complaints such as tearing, pain, burning sensation or vision loss, under **COMMENTS**

**Eye Sensation Record**

If blink is normal do not test sensation. If lid closure or blink frequency are abnormal test sensation as shown. Record by comment whether: normal/reduced/absent.

1. The assessor should wash hands before testing, then make a point out of a wisp of cotton wool and explain the test to the patient.
2. The patient should look to the opposite side and upwards as illustrated, covering other eye.
3. The assessor should:
   - approach from the side
   - touch the edge of the cornea, and
   - observe and record whether the patients reaction (i.e. his eye sensation) is:
     - normal, reduced or absent.
Vision Record

- Test sensation with good light falling on the assessor.
- Ask the patient to cover one eye, and then count the numbers of fingers that the assessor holds up.
- Test at 6 metres. If the patient cannot see at 6 metres, retest at 3 metres.

Record vision under COMMENTS e.g.

<table>
<thead>
<tr>
<th>DATE</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>25/6/92</td>
<td>Vision counting fingers: Right eye - 3 metres, Left eye - 0 metres.</td>
</tr>
</tbody>
</table>

WHO disability grading (eye):
Grade 2 = the patient cannot count fingers at 6 metres.

Voluntary Muscle Test (VMT) Lid Record

The assessor should test and record the strength of the action illustrated on the right. Lid gap is recorded in mm. on light closure to test facial nerve function.

- The patient is asked to close the eyes lightly as in sleep.
- The assessor measures and records any gap in mm
- If closure is normal he records “0 mm”.
Annex 7: Self Care of Eyes with blink problems

1. AVOID INJURY THROUGHOUT THE DAY
   a) Blink consciously
      Try to close with effort regularly
   b) Think when the dust blows or when winnowing
      Make 'think-and-blink' a habit
   c) Protect your eyes from wind/dryness
      sun and heat
   d) Keep your eyes clean and free from flies
   e) Cover your eyes at night

2. FOLLOW THIS DAILY ROUTINE
   a) Inspect once or twice daily for dirt
      and redness:
      - using a mirror
      - ask someone (relative) to inspect
   b) Remove foreign bodies by repeated 'think-and-blink'
      or very gently with a clean cloth

3. HEAL WOUNDS QUICKLY
   In case of irritation,
   vision change and/or injury:
   a) Report to a health visitor
   b) Apply any prescribed ointment without
      touching the eye with the tube
## Annex 8: Self Care of Hands without feeling (01)

### I AVOID INJURY THROUGHOUT THE DAY

<table>
<thead>
<tr>
<th>RECOGNISE DANGER</th>
<th>AVOID</th>
</tr>
</thead>
<tbody>
<tr>
<td>a) Beware of hot objects</td>
<td>Insulate</td>
</tr>
<tr>
<td>Allow to cool</td>
<td>Keep distance</td>
</tr>
<tr>
<td>b) Beware of pressure build-up</td>
<td>Change jobs often</td>
</tr>
<tr>
<td></td>
<td>Cushion tool handles</td>
</tr>
<tr>
<td></td>
<td>Stop for rests</td>
</tr>
<tr>
<td>c) Beware of sharp or rough objects</td>
<td>Smooth them</td>
</tr>
<tr>
<td></td>
<td>Keep distance</td>
</tr>
<tr>
<td></td>
<td>Use tough gloves</td>
</tr>
</tbody>
</table>
Annex 8: Self Care of Hands without feeling (02)

2 FOLLOW THIS DAILY ROUTINE

a) Inspect for:
   - signs of injury
   - hard skin

b) Soak

c) Rub off hard skin at:
   - crack edges
   - old wound sites

d) Excercise

e) Oil well

3 HEAL WOUNDS QUICKLY - AVOID RECURRENCE

a) Work out the wound cause

b) Plan how to avoid recurrence

C) Clean
   Cover
   Rest

the wound

d) Check for healing

e) If no improvement, replan care and report to health staff
I AVOID INJURY THROUGHOUT THE DAY

Remember
most sole wounds are:
- at walking pressure sites
- caused by walking too much

Only by:
- walking less and/or
- using more protective shoe insoles
can you lessen risk of such injury

a) Learn how far you can walk without sole injury

b) Buy footwear with well cushioned insoles, hard undersoles and no nails or rough edges that would hurt your feet*

c) Avoid long walks

d) Keep feet well away from the fire
Non feeling skin burns easily

e) Avoid sitting cross-legged
risk of ankle bone injury
2 FOLLOW THIS DAILY ROUTINE
a) Inspect for:
   - signs of injury
   - hard skin
d) Oil well
b) Soak
e) Exercise
c) Rub off hard skin at:
   - crack edges
   - old wound sites

3 HEAL WOUNDS QUICKLY - AVOID RECURRENCE
a) Inspect to find wounds early
   Work out cause and plan
   how to avoid recurrence
b) Clean and cover the wound
c) Rest the wound
   Avoid pressure on it, imagine
   wound pain
d) Check for healing
   "It's smaller Good!"
e) If no improvement, replan
   care and report to health staff

CARE OF DROPPED FOOT
a) Use a footdrop support  b) Exercise
### Annex 10: Protective Footwear

#### Implementation Tasks

| Task 1 : Identify patients with sole sensory loss | Identification |
| Task 2 : Advise patients what footwear to buy and where to obtain it according to managers guidelines | Availability Suitability |
| Task 3 : Train patients to understand: - what makes footwear protective - the importance of using protective footwear whenever walking or standing - possible sources - safe repair without nails or wire | Patients' usage of suitable footwear Repairs safe |
| Task 4 : Monitor usage, state of wear, sole wound recurrence Identify causes of non-use (e.g. the footwear has become known as 'leprosy footwear', or is inappropriate for work), of poor wear or delay in obtaining footwear. Report footwear problems to supervisor. If sole wounds recur discuss with the patient any possibilities of improved insole cushioning and/or less walking | Monitor footwear usage, durability, safe repair Solve problems or report to manager |

### Possible Sources of Protective Footwear Include the Following:

- **a)** Sports footwear that incorporates good insole cushioning
- **b)** Modified shop sandals Straps lengthened and soft insole added
- **c)** Footwear can be deepened by 1 cm and a soft insole added by: local shoe makers, factories, hospital-workshop
- **d)** Heel strap added to house slippers

**Note.** Soft slipper sole, with straps removed and the holes plugged with the same material, can be used as insoling material.

**Use of protective, cushioned footwear by the majority needing it is the priority. Patients should be encouraged to buy their own unless destitute, using suitable local shop footwear. Where this is not available it may be necessary to organise distribution of footwear for sale to patients, through district leprosy supervisors. Where special shoe workshops exist, their staff can focus attention on modifying footwear for patients whose wounds recur with the simpler footwear.**
1 Registration Data

Name and address of health facility:

..........................................................................................................................................................

Patient registration number: ..............................................................................................................

Date of registration: ............................................................................................................................

2 Personal Data

Name of the patient:

..........................................................................................................................................................

Sex:    Male / Female       Year of birth (or age): …………………   Place of birth:………………

Present address    Permanent address    Nationality:

..........................................................................................................................................................

Number of years of residence at present address:

..........................................................................................................................................................

Telephone number: .............................................................................................................................

Occupation: .........................................................................................................................................

Marital status: Single/married/widow

Mode of detection: Contact survey/other surveys/voluntary/referred/ others (specify)

..........................................................................................................................................................

Previous treatment details (Specify drug regimen, duration and year of previous treatment):

..........................................................................................................................................................

Patient Status: New/relapse after PB MDT/relapse after MB MDT/transfered in/readmission after DDS monotherapy/treatment after default

Contact History (Any known leprosy patient within the family) – Yes / No

Details of household contacts

Serial number  

1 ........................................................................................................................................................

2 ........................................................................................................................................................

3 ........................................................................................................................................................

4 ........................................................................................................................................................

5 ........................................................................................................................................................

6 ........................................................................................................................................................
### Disease Status (Initial) – Leprosy

<table>
<thead>
<tr>
<th>Presenting symptoms</th>
<th>Patch/es, visible impairment, reactions, other (specify)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration of presenting symptoms (in months &amp; years)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Numbers of skin patches</th>
<th>One</th>
<th>2 – 5</th>
<th>&gt;5</th>
</tr>
</thead>
</table>

Reactions – please encircle (Yes/ No); If yes, please encircle (Type 1 / Type 2)

<table>
<thead>
<tr>
<th>Nerve status</th>
<th>Ulnar</th>
<th>Median</th>
<th>Radial</th>
<th>LPN</th>
<th>PT</th>
</tr>
</thead>
<tbody>
<tr>
<td>R</td>
<td>L</td>
<td>R</td>
<td>L</td>
<td>R</td>
<td>L</td>
</tr>
<tr>
<td>Thickening/ Pain/ Tenderness</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>WHO disability grading (At the time of diagnosis)</th>
<th>Eye</th>
<th>Hand</th>
<th>Foot</th>
</tr>
</thead>
<tbody>
<tr>
<td>Right</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**WHO grading for the eyes:**

<table>
<thead>
<tr>
<th>Grade</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>No severe visual impairment (can count fingers at 6 meters; visual acuity. 6:60). No visible impairments. Normal blink reflex.</td>
</tr>
<tr>
<td>1</td>
<td>Loss of blink reflex and/or inability to hold the eyelids closed against moderate force to open them. No severe visual impairment (can count fingers at 6 meters – visual acuity. 6:60).</td>
</tr>
<tr>
<td>2</td>
<td>Visible impairments to the eye, severe visual impairment (cannot count fingers at 6 meters – visual acuity, 6:60) and/or any other visible damage to the eye (regardless of cause).</td>
</tr>
</tbody>
</table>

**WHO disability grading for the hands:**

<table>
<thead>
<tr>
<th>Grade</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Touch is felt on the palm of the hand; no muscle weakness or visible impairment.</td>
</tr>
<tr>
<td>1</td>
<td>At least 2 points on the hand where touch is not felt and/or muscle weakness is present on testing, but there is no visible impairment.</td>
</tr>
<tr>
<td>2</td>
<td>Visible impairment of the hand if it has occurred since the onset of loss of sensation and/or loss of muscle function due to leprosy</td>
</tr>
</tbody>
</table>

**WHO disability grading for the feet:**

<table>
<thead>
<tr>
<th>Grade</th>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>Awareness of sensation on the soles of feet; no muscle weakness or visible impairment.</td>
</tr>
<tr>
<td>1</td>
<td>At least 2 points on the foot where touch is not felt and/or muscle weakness is present (on testing) but there is no high stepping gait when the patient walks and there is no other visible impairment.</td>
</tr>
<tr>
<td>2</td>
<td>Visible impairment of the foot if it has occurred since the onset of loss of sensation and / or loss of muscle function due to leprosy. High stepping gait when the patient walks (obvious foot drop).</td>
</tr>
</tbody>
</table>

**EHF Score (At the time of diagnosis)**

EHF Score is the sum of all the individual disability grades for the two eyes, two hands and two feet. Since the disability grade can be scored as either 0, 1 or 2, it follows that the EHF score ranges from 0 to 12. A score of 12 would indicate grade-2 disability of both eyes, both hands and both feet.
**4 Details of Other Conditions:**
Medical History: (Mention Yes / No)

<table>
<thead>
<tr>
<th>Diabetes</th>
<th>Hepatitis</th>
<th>Tuberculosis</th>
<th>HIV/AIDS</th>
<th>Any other disease:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Other conditions:

- Pregnant
- Drug allergy

**General Physical Examination:**

- ……………………………………………………………………………………………………………………………………………………………………………
- ……………………………………………………………………………………………………………………………………………………………………………
- ……………………………………………………………………………………………………………………………………………………………………………
- ……………………………………………………………………………………………………………………………………………………………………………
- ……………………………………………………………………………………………………………………………………………………………………………

Body weight: ………………………

**5 Treatment Details**

<table>
<thead>
<tr>
<th>Drug regimen prescribed (tick the appropriate column)</th>
<th>PB MDT</th>
<th>MB MDT</th>
<th>Any other regimen (specify)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Treatment Monthly Attendance (Schedule of Monthly Supervised Doses)

<table>
<thead>
<tr>
<th>Dose</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dose</td>
<td>7</td>
<td>8</td>
<td>9</td>
<td>10</td>
<td>11</td>
<td>12</td>
</tr>
<tr>
<td>Date</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Date of treatment completion</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcome of treatment</td>
<td>(default, died, transferred out, change of classification)</td>
</tr>
</tbody>
</table>

### 6 Bacteriological Examination (Slit skin smear)

<table>
<thead>
<tr>
<th>Date</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of sites taken</td>
<td></td>
</tr>
<tr>
<td>Highest BI at any one site</td>
<td></td>
</tr>
<tr>
<td>Average BI</td>
<td></td>
</tr>
</tbody>
</table>

### 7 Assessment of Disability & Nerve Function

#### Voluntary Muscle Test

<table>
<thead>
<tr>
<th>Date</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Vision (0,1,2)</td>
<td></td>
</tr>
<tr>
<td>Light closure lid gap in mm. Blink present / absent</td>
<td></td>
</tr>
<tr>
<td>Little finger out</td>
<td></td>
</tr>
<tr>
<td>Thumb up Wrist extension Foot up</td>
<td></td>
</tr>
<tr>
<td>Disability grade hands</td>
<td></td>
</tr>
<tr>
<td>Disability grade feet</td>
<td></td>
</tr>
<tr>
<td>Disability grade eyes</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>On date</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Max. (WHO) Disability Grade</td>
<td></td>
</tr>
<tr>
<td>EHF score</td>
<td></td>
</tr>
</tbody>
</table>

#### Muscle power:

- **S** = Strong
- **W** = Weak
- **P** = Paralysis
- **W** = Weak

<table>
<thead>
<tr>
<th>Score of vision: counting fingers at 6 meters</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 = Normal</td>
</tr>
<tr>
<td>1 = Blurring vision</td>
</tr>
<tr>
<td>2 = Unable to count fingers</td>
</tr>
</tbody>
</table>
Sensory Testing

<table>
<thead>
<tr>
<th>Date</th>
<th>PALM</th>
<th>SOLE</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RIGHT</td>
<td>LEFT</td>
<td>RIGHT</td>
</tr>
<tr>
<td></td>
<td>RIGHT</td>
<td>LEFT</td>
<td>RIGHT</td>
</tr>
<tr>
<td></td>
<td>RIGHT</td>
<td>LEFT</td>
<td>RIGHT</td>
</tr>
</tbody>
</table>

Key: (Put these marks/icons on the site where lesion is seen)
U Sensation Present within 3 cm  S Contracture  O Scar/Callus  ⇔ Wound  ↓ Shortening Level  £ Anaesthesia \ Crack

8 Notes
Record reactions (indicate Type 1 or Type 2); complications; relapse, etc

<table>
<thead>
<tr>
<th>Date</th>
<th>Notes (signs &amp; symptoms; diagnosis; treatment details)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Bibliography

- Common skin diseases in Africa 2001, C. van Hees, B. Naafs
- Essential Action to Minimise Disability in Leprosy; 1988; Jean M. Watson; ILEP
- Learning Guide One: Diagnosis and treatment of leprosy. 2002, ILEP.
- Learning Guide Two: How to recognize and manage leprosy reactions. 2002, ILEP.
- Learning Guide Three: How to do a skin smear examination for leprosy. 2003, ILEP.
- Learning Guide Four: How to prevent disability in leprosy. 2006, ILEP.
- Leprosy Manual; 2008, Ministry of Health Zambia
- Technical Guide: Facilitating the integration process. 2003, ILEP.
- National Manual for Leprosy Control in Nepal; 1997; MOH, Leprosy control division; second and third edition;
- Operational Guidelines for the implementation of the Global Strategy; WHO for Further Reducing the Leprosy Burden and Sustaining Leprosy Control Activities 2006 – 2010, WHO
- Revised Workers Manual, National Tuberculosis and Leprosy Control Program, Nigeria; 1998; Federal Ministry of Health, Nigeria
- Self-Care Groups – A manual for leprosy control programs: 2005; Directorate General of Communicable Disease Control and Environmental Health; Netherlands Leprosy Relief (NLR)
- Technical Guide: Meeting the needs of people affected by leprosy through CBR. 2006 ILEP
- The Global Strategy for further reducing the leprosy burden and sustaining leprosy control activities (Plan period 2006 – 2010), WHO
- Wound care for people affected by leprosy. ALM 2003, H. Cross